Eli Lilly Puts Up $60M for In Vivo Gene-Editing Med for Cardiovascular Disease Healthcare Resources By On Jun 15, 2023 0 Share Eli Lilly’s partnership with Verve Therapeutics covers the development of a preclinical therapy addressing a protein associated with cardiovascular disease risk. The in vivo gene-editing therapy is a potential one-time treatment. 0 Share